A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies

Trial Profile

A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 26 Oct 2017 According to an Omeros Corporation media release, a case report of a patient who had a difficult post-transplant course, including steroid-resistant GvHD and cytomegalovirus infection, was reported last week at the EBMT Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT.
    • 26 Oct 2017 Results published in an Omeros Corporation media release.
    • 20 Oct 2017 According to an Omeros Corporation media release, a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft-versus-host disease (GvHD), which both resolved following OMS721 treatment was presented at the European Society for Blood and Marrow Transplantation (EBMT) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top